0      0

The Evidence Behind the Research: FGF-23 and Its Impact on CKD

‐ Sep 21, 2013 1:30pm

Contact hours available until 9/22/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Conflict of Interest Disclosure:
Speaker(s) have no disclosures to declare.

Conference Committee Disclosures:
Dawn Koonkongsatian – Employee, Fresenius Medical Care
Kristin Larson – Employee, NxStage Medical
Denise Murcek – Employee, Fresenius Medical Care
Beth St. John - Employee, Fresenius Medical Care
Lucy Todd – Employee, Baxter Healthcare
Kyra Trappett – Employee, DaVita

Commercial Support and Sponsorship:
Supported by an unrestricted educational grant from Sanofi Renal.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

  • Examine the pathophysiology of metabolic bone disease (MBD) and the importance of FGF-23 and klotho on MBD.
  • Discuss important research findings related to FGF-23 and Klotho and their impact on CKD patients.
  • Determine the changes necessary in policies and practices to improve the management of MBD based upon this new data.


You must be logged in and own this session in order to post comments.